OBJECTIVE: To compare serum levels of MCP-1/CCL2, RANTES/CCL5, and Eotaxin/CCL11 between female patients with recurrent major depressive disorder (MDD) and healthy controls, verifying if there is a difference in the levels of these mediators between those with or without current suicidal ideation. METHODS: Thirty female outpatients with recurrent MDD were divided in two groups accordingly the presence or absence of suicidal ideation. These groups were compared with 16 healthy controls. Serum levels of MCP-1/CCL2, RANTES/CCL5, and Eotaxin/CCL11 were determined. Depression severity was evaluated by Beck Depression Inventory (BDI). Suicidal ideation was assessed by SCID-I and BDI. RESULTS: Patients with recurrent MDD and healthy controls did not differ in age, socioeconomic status, and education. All patients reported high scores of BDI (mean, SD, n; 29.75, 10.55, 28). Multivariable analysis of covariance adjusted for age and BMI showed that MDD patients with suicidal ideation presented lower levels of MCP-1/ CCL2 and RANTES/CCL5 (p < 0.001) and higher levels of Eotaxin/CCL11 (p = 0.04) compared to healthy controls. These differences remained significant after adjusting for depression severity. CONCLUSION: The findings of this study indicated that the presence of recurrent MDD with suicidal ideation is associated with differences in inflammatory chemokines when compared to those without suicidal ideation.
OBJECTIVE: To compare serum levels of MCP-1/CCL2, RANTES/CCL5, and Eotaxin/CCL11 between female patients with recurrent major depressive disorder (MDD) and healthy controls, verifying if there is a difference in the levels of these mediators between those with or without current suicidal ideation. METHODS: Thirty female outpatients with recurrent MDD were divided in two groups accordingly the presence or absence of suicidal ideation. These groups were compared with 16 healthy controls. Serum levels of MCP-1/CCL2, RANTES/CCL5, and Eotaxin/CCL11 were determined. Depression severity was evaluated by Beck Depression Inventory (BDI). Suicidal ideation was assessed by SCID-I and BDI. RESULTS:Patients with recurrent MDD and healthy controls did not differ in age, socioeconomic status, and education. All patients reported high scores of BDI (mean, SD, n; 29.75, 10.55, 28). Multivariable analysis of covariance adjusted for age and BMI showed that MDDpatients with suicidal ideation presented lower levels of MCP-1/ CCL2 and RANTES/CCL5 (p < 0.001) and higher levels of Eotaxin/CCL11 (p = 0.04) compared to healthy controls. These differences remained significant after adjusting for depression severity. CONCLUSION: The findings of this study indicated that the presence of recurrent MDD with suicidal ideation is associated with differences in inflammatory chemokines when compared to those without suicidal ideation.
Authors: Harris A Eyre; Tracy Air; Alyssa Pradhan; James Johnston; Helen Lavretsky; Michael J Stuart; Bernhard T Baune Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2016-02-20 Impact factor: 5.067
Authors: D S Pisetsky; S E Trace; K A Brownley; R M Hamer; N L Zucker; P Roux-Lombard; J-M Dayer; C M Bulik Journal: Cytokine Date: 2014-06-14 Impact factor: 3.861
Authors: Stephen F Smagula; Helmet T Karim; Eric J Lenze; Meryl A Butters; Gregory F Wu; Benoit H Mulsant; Charles F Reynolds; Howard J Aizenstein Journal: Int J Geriatr Psychiatry Date: 2016-09-19 Impact factor: 3.485
Authors: Bharathi S Gadad; Manish K Jha; Bruce D Grannemann; Taryn L Mayes; Madhukar H Trivedi Journal: J Psychiatr Res Date: 2017-05-26 Impact factor: 4.791
Authors: Vivian C Romero; Emily C Somers; Valerie Stolberg; Chelsea Clinton; Stephen Chensue; Zora Djuric; Deborah R Berman; Marjorie C Treadwell; Anjel M Vahratian; Ellen Mozurkewich Journal: Am J Obstet Gynecol Date: 2013-04 Impact factor: 8.661
Authors: Stephen F Smagula; Francis E Lotrich; Howard J Aizenstein; Breno S Diniz; Jeffrey Krystek; Gregory F Wu; Benoit H Mulsant; Meryl A Butters; Charles F Reynolds; Eric J Lenze Journal: Int J Geriatr Psychiatry Date: 2016-06-10 Impact factor: 3.485
Authors: Olivia Bauer; Vladimir M Milenkovic; Sven Hilbert; Nina Sarubin; Johannes Weigl; Lisa-Marie Bahr; Thomas C Wetter; Barbara Heckel; Christian H Wetzel; Rainer Rupprecht; Caroline Nothdurfter Journal: Neuroimmunomodulation Date: 2021-01-27 Impact factor: 2.492